Canada Liver Diseases Therapeutics Market Insight
Canada liver diseases therapeutics market size is growing at a 5.85% CAGR, driven by the increasing prevalence of liver disorders such as hepatitis, non-alcoholic fatty liver disease (NAFLD), and liver cancer. In the rising healthcare awareness, advancements in antiviral and biologic therapies, and growing demand for early diagnosis and treatment are supporting market expansion across hospitals and specialty clinics.
Canada Liver Diseases Therapeutics Market Insights Forecasts to 2035
- The Canada Liver Diseases Therapeutics Market Size Was Estimated at USD 1.97 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 5.85% from 2025 to 2035
- The Canada Liver Diseases Therapeutics Market Size is Expected to Reach USD 3.48 Billion by 2035
Notable Insights for Canada Liver Diseases Therapeutics Market
- By disease type, the hepatitis segment dominates the Canada liver diseases therapeutics market, driven by high treatment uptake for chronic HBV and HCV infections, generating approximately USD 270 million in revenue in 2024.
- By treatment type, the antiviral drugs segment is the fastest growing in the Canada liver diseases therapeutics market, driven by rising HBV and HCV treatment adoption and strong clinical pipeline expansion, accounting for approximately 36-40% market share in 2025.
- Gilead Sciences has generated total revenue of approximately USD 27 billion in 2025, maintaining a strong position in liver disease therapeutics, particularly antiviral treatments
- According to Public Health Agency of Canada, over 250,000 Canadians are living with hepatitis B, highlighting a significant treatment demand across the country
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the Canada liver diseases therapeutics market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in Canada Liver Diseases Therapeutics Market
-
- Gilead Sciences
- AbbVie
- Bristol-Myers Squibb
- Roche
- Pfizer
- Novartis
- Others
Recent Developments:
- In January 2026, Canada’s liver diseases therapeutics market advanced as preclinical MASH/NASH candidate EVT0185 by Espervita Therapeutics at McMaster University bolstered pipeline expansion, supporting projected CAD 210 million market growth and rising NAFLD treatment adoption.
- In April 2026, GSK Canada filed a priority New Drug Submission for bepirovirsen, strengthening the Hepatitis segment of the Canada liver diseases therapeutics market, projected at USD 320 million in 2025, driving innovation and market growth.
Market Segmentation:
Canada Liver Diseases Therapeutics Market, By Disease Type
-
- Hepatitis
- Non-Alcoholic Fatty Liver Disease (NAFLD)
- Alcohol-Induced Liver Disease
- Liver Cancer
Canada Liver Diseases Therapeutics Market, By Treatment Type
-
- Antiviral Drugs
- Chemotherapy
- Immunosuppressive Agents
- Corticosteroids
Canada Liver Diseases Therapeutics Market, By End User
-
- Hospitals
- Specialty Clinics
- Ambulatory Care Centers
Expert Views:
The Canada liver diseases therapeutics market is projected to expand at a steady rate due to rising disease incidence as well as advances in therapeutics. According to industry specialists, hepatitis and antivirals will be key drivers of this market, as will developments in biologics, precision medicine, and early diagnosis technologies.